Get the Stockscreener App
1.96
3.16%
0.06
After Hours:
1.95
-0.01
-0.51%
Cardiol Therapeutics Inc stock is traded at $1.96, with a volume of 235.85K.
It is up +3.16% in the last 24 hours and down -0.51% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.90
Open:
$1.9
24h Volume:
235.85K
Relative Volume:
0.57
Market Cap:
$151.21M
Revenue:
-
Net Income/Loss:
$-20.75M
P/E Ratio:
-5.5825
EPS:
-0.3511
Net Cash Flow:
$-23.71M
1W Performance:
+7.10%
1M Performance:
-0.51%
6M Performance:
-1.51%
1Y Performance:
+131.54%
1-Day Range:
$1.8989
$1.97
1-Week Range:
$1.75
$1.97
52-Week Range:
$0.72
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Comparing Cardiol Therapeutics (NASDAQ:CRDL) and IN8bio (NASDAQ:INAB) - Defense World
Top 4 Canadian Biotech Stocks of 2024 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Shares Down 0.8% – Should You Sell? - Defense World
Cardiol Therapeutics (TSE:CRDL) Trading Down 0.8%Should You Sell? - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short Interest - MarketBeat
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
Equities Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for CRDL Earnings - Defense World
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Shares Acquired by Foundations Investment Advisors LLC - Defense World
HC Wainwright Reiterates "Buy" Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? - MSN
Cardiol Therapeutics advances CardiolRx in new trial By Investing.com - Investing.com Australia
Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx Trademark - openPR
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside… - Barchart
Cardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trial - Proactive Investors Australia
Cardiol Therapeutics advances CardiolRx in new trial - Investing.com
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Newsfile
Troutman Pepper Advises Cardiol Therapeutics in Closing of Over-Allotment Option - Troutman Pepper
Cardiol Therapeutics (FRA:CT9) Operating Cash Flow per Shar - GuruFocus.com
Gold SPDR (GLD-A) QuotePress Release - The Globe and Mail
Deeper Dive: Understanding Cardiol Therapeutics Inc (CRDL) Through its Various Ratios - The Dwinnex
Cardiol Therapeutics raises $15.5M following over-allotment option exercise - Proactive Investors USA
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Yahoo Finance
Cardiol Therapeutics Inc [CRDL] is 117.03% higher this YTD. Is it still time to buy? - The DBT News
Get in on Cardiol Therapeutics Inc’s (CRDL) buy-in window today! - SETE News
Cardiol Therapeutics closes $13.5M offering - Proactive Investors USA
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - StockTitan
CRDL’s 2023 Market Dance: Up 90.31% – Time to Invest? - The InvestChronicle
Examining CRDL’s book value per share for the latest quarter - US Post News
Cardiol Therapeutics (TSE:CRDL) Trading Down 19.7%Here's What Happened - MarketBeat
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today - Benzinga
Cardiol Therapeutics prices $13.5M public offering - Proactive financial news
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Investing News Network
Cardiol Therapeutics announces public offering of shares By Investing.com - Investing.com South Africa
Cardiol Therapeutics Announces Public Share Offering - TipRanks
Cardiol Therapeutics announces public offering of shares - Investing.com
SEC Form SUPPL filed by Cardiol Therapeutics Inc. - Quantisnow
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares - Newsfile
TSX Composite Banks Index (TXBA) QuotePress Release - The Globe and Mail
Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart) - Investing News Network
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Pericarditis Drugs Market to Boost Revenue Potential, - openPR
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.6% - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.1% - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Up 1.1% - Defense World
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - Investing News Network
Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial - Proactive Investors UK
Cardiol Therapeutics’ Landmark Enrollment for Heart Drug Trial - TipRanks
Cirion debuts voice and collaboration service in Chile - Telecompaper EN
Guardion Health Sciences announces executive shake-up - Investing.com India
Returns On Capital At Churchill Downs (NASDAQ:CHDN) Have Stalled - Simply Wall St
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):